TDOC - TDOC テラドック・ヘルス （）

It''s not only investors who are getting more bearish on the company in the wake of its latest earnings release.

Teladoc Health, Inc. (NYSE:NYSE:TDOC) Cowen 43rd Annual Healthcare Conference March 6, 2023 12:50 PM ETCompany ParticipantsPatrick Feeley - Head, Investor RelationsMala Murthy - Chief…

https://www.investing.com/news/pro/teladoc-pt-lowered-to-36-at-canaccord-genuity-432SI-3022864

Teleadoc (TDOC)-owned metal health firm BetterHelp has agreed to pay $7.8M in a deal with the Federal Trade Commission ((FTC)) over allegations of data misuse. Read the full story here.

In the current trading session, Teladoc Health Inc.’s (TDOC) stock is trading at the price of $26.83, a fall of -0.63% over last night’s close. So, the stock is trading at a price that is -66.42% less than its 52-week high of $79.90 and 24.21% better than its 52-week low of $21.60. Based on the […]

Teleadoc (TDOC)-owned metal health firm BetterHelp has agreed to pay $7.8M in a deal with the Federal Trade Commission ((FTC)) over allegations of data misuse. Read the full story here.

In the current trading session, Teladoc Health Inc.’s (TDOC) stock is trading at the price of $26.83, a fall of -0.63% over last night’s close. So, the stock is trading at a price that is -66.42% less than its 52-week high of $79.90 and 24.21% better than its 52-week low of $21.60. Based on the […]

Teladoc has held its January lows resiliently, despite being battered by a weak outlook for 2023. Read why we reiterate a speculative buy rating for TDOC stock.

https://www.investing.com/news/pro/teladoc-hits-low-down-375-432SI-3015775

https://www.investing.com/news/pro/teladoc-pt-lowered-to-33-at-jpmorgan-432SI-3015411

The Fed’s key interest rate target now stands at 3%-3.25%, way up from 0%-0.25% at the beginning of the year. That means, for all companies, borrowing money is becoming much more expensive. As a result, healthcare companies losing a great deal of money will have trouble obtaining new loans they can afford to pay off, and many such firms will go out of business. For investors, it’s essential to avoid the stocks of such companies, and some readers may even want to consider selling the shares of these firms short. To help achieve those goals, I will identify three healthcare stocks to sell before they die. There are a few other important points to consider before reading this column. First, it takes drug makers at least several years to identify a promising drug candidate. Then, it has to run clinical trials, and obtain FDA approval. And the vast majority of drug candidates fail to obtain FDA approval. Meanwhile, due to the increase in interest rates and the Fed’s quantitative tightening program, institutional investors will be much less likely to speculate on healthcare companies that are losing a great deal of money and have little chance of making comebacks.

This telehealth company is down but not out yet.

RBC Capital Markets has cut the price target for Teladoc Health Inc (NYSE: TDOC ) from $53 to $35 but reiterates the Outperform rating . The analyst urges some near-term caution into late-October Q3 results based on an increased risk to the guidance given the continued deterioration in the BetterHelp consumer backdrop, particularly into Q4 as mgmt intends to curtail ad spending significantly. RBC does not expect … Full story available on Benzinga.com

Can this telemedicine leader rebound?

A few years ago, telehealth services were in a nascent stage, but in 2022, the industry is vibrant and growing, thanks largely to the pandemic. In this piece, we used TipRanks'' Comparison Tool to evaluate two telehealth stocks — TDOC and DOCS. Doximity (NYSE: DOCS) is highly profitable, while Teladoc (NYSE: TDOC) has never been profitable on a GAAP basis. As a result, a bullish view seems appropriate for Doximity in light of this year''s sell-off, while Teladoc seems more deserving of a bearish-to-neutral view.